If claiming for a Documented Loss Cash Payment for the AT&T 1 Data Incident and a Documented Loss Cash Payment for the AT&T 2 ...

In the study, Raza and colleagues reviewed data from 214 adults who underwent BLVR at a single center between January 2018 ...

Rhythm Pharmaceuticals (RYTM) announced that Rhythm and its partners delivered four Rhythm data presentations at ObesityWeek 2025, held last week ...

As neural implant technology and A.I. advance at breakneck speeds, do we need a new set of rights to protect our most ...

Open-label prophylaxis data supporting the long-term safety profile and sustained benefits of deucrictibant, as well as clinical validation data of a kinin biomarker assay were highlighted in two oral ...

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) Q3 2025 Earnings Call Transcript November 12, 2025 Acumen Pharmaceuticals, Inc.

The Ottawa Police Service tabled its draft budget with a five-per-cent increase that Chief Eric Stubbs said was necessary to ...

Washington State University (WSU) is undergoing a significant system-wide redesign aimed at modernizing its campuses and ...

Multiple Late-Stage Data Readouts Reinforce Telitacicept's Broad Potential Across Autoimmune DiseasesExpansion of Executive Leadership and Board Strengthens Global Development Capabilities Expected gr ...

Therapeutics presented new data from the ongoing REZOLVE-AD Phase 2b study in a late-breaking oral abstract presentation at the ...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) Q3 2025 Earnings Call Transcript November 12, 2025 Acurx Pharmaceuticals, Inc.

Presented detailed efficacy and safety results from the PIK3CA wild-type ("WT") cohort of the Phase 3 VIKTORIA-1 clinical trial at a late breaking oral presentation at the 2025 European Society for Me ...